Vijay Pande Shares Essential Investment Insights from His $4 Billion Experience at a16z

Vijay Pande initially established his reputation in the academic realm before making a significant foray into the investment world. This pivot started nearly a decade ago when Marc Andreessen and Ben Horowitz, who had previously hesitated to invest in healthcare and life sciences, opted to explore this space by appointing Pande to lead their efforts. At that time, he was a well-known chemistry professor at Stanford, celebrated for his creation of Folding@home, a distributed computing initiative that transformed countless personal computers into a supercomputer dedicated to disease research. Over the following ten years, he significantly enhanced a16z’s investment activities, overseeing nearly $4 billion.

Last June, Pande made a surprising decision to reduce his extensive responsibilities and establish a smaller venture. His new firm, VZVC, co-founded with veteran investor Zach Werner, aims to execute a limited number of focused investments each year instead of diversifying across various projects. Operating without additional team members, the firm heavily incorporates AI into its processes.

To explore Pande’s pivotal transition, we engaged in a discussion about his recent decision to focus on a select few investments rather than spreading resources too thin in today’s market climate. We also examined an intriguing challenge in AI-driven biotechnology: unlike textual data, biological information isn’t readily accessible online, leading to the necessity of creating isolated datasets. What consequences does this have for potential medical breakthroughs, and who stands to gain?

This conversation has been streamlined for clarity and conciseness. You can also listen to the full discussion (below).

You mentioned that biology is evolving from a “science of discovery” into an engineering discipline. What does that mean?

Historically, drug development was riddled with uncertainty. The major shift today is that AI and machine learning can analyze complex data to pinpoint drug targets for specific diseases, assist in the drug creation process, and even improve clinical trials—the most expensive segment of the development pipeline.

I’ve heard that clinical trials are becoming less expensive due to synthetic data, which diminishes the need for participants.

That’s a hopeful viewpoint. While initial costs and timelines for clinical trials have indeed been reduced, particularly with the aid of AI, conducting a trial can still cost hundreds of millions of dollars, contributing to the high expenses of new therapies. The probability of a drug advancing from the initial trial to phase three is merely 20%. Given that 80% of trials fail and considerable costs are tied to each, expenses can escalate quickly. Most failures aren’t the result of biologists’ errors but stem from testing drugs on animal models, like mice, which often do not mimic human responses accurately. While AI models are not infallible, they usually surpass animal models, opening exciting new avenues.

[The next question is]: Is this drug the right one for me?

You’re referencing personalized medicine…

What you’re looking for is precision medicine. When patients present complex conditions to doctors, physicians often have to make educated guesses due to insufficient data. They may prescribe one medication, and if it fails, they try another, and so forth. This occurrence is particularly prevalent in cancer treatment and similar cases. It would be incredibly beneficial if the first medication prescribed was the correct one. Currently, blood test results are compared against general population averages, but they should be personalized to showcase what is distinct for each patient. We are beginning to improve our understanding of which treatments are most effective for each individual.

Do you think this progress has been gradual, or has it accelerated recently?

I believe this change has emerged from several overlapping factors. For a prolonged period, precision medicine primarily focused on genomics. However, the human genome serves as a foundational base for a “structure” that evolves. Now, various other measurable factors, like proteomics, provide more relevant insights into diseases and health issues. Additionally, advancements in robotics and automation align closely with AI, creating beneficial synergies.

Over the past decade, we’ve witnessed steady advancements in the integration of AI within biology and chemistry. The biological focus concentrates on disease treatment, while the chemistry angle emphasizes drug development targeting specific proteins. Indeed, remarkable progress has been made during this period.

You indicated that biology is one of the few fields where data isn’t readily accessible online. What are the implications for the field’s advancement?

This suggests a lack of shared datasets that organizations could collaboratively use to train their models. This absence creates distinctive challenges from an AI perspective.

Doesn’t this highlight a persistent issue in medicine, where practitioners often work in competitive silos?

You’ve pinpointed an important issue. When a patient is diagnosed with a particular cancer type that involves both oncology and endocrinology, specialists from each field frequently do not collaborate effectively. AI holds exciting potential due to its ability to integrate knowledge across multiple disciplines, mirroring the cooperative efforts of leading physicians.

Is there sufficient data sharing to achieve this vision? I understand that founders and investors may want to protect their innovations…

I’m observing a considerable movement toward developing comprehensive biological information atlases, which are often constructed as foundational models. As these become more widespread, I foresee a trend similar to the one we’ve witnessed with open-source large language models that have surpassed corporate options: open-source foundational models in biology will exert significant influence.

You have ties to Genesis Therapeutics, which originated in your Stanford lab, and Insitro, the drug-discovery company founded by your former colleague, Daphne Koller. Additionally, you’re collaborating on a venture with a founder you’ve known for twenty years. What traits do you value in founders, and what sectors are you focusing on?

I’m focusing on two main areas: AI for healthcare delivery, which I researched extensively at a16z, and AI for clinical trials.

Trust is crucial for me when evaluating founders. I seek partners with integrity—individuals who honor their commitments. My goal is to cultivate a relationship that lasts 5 to 10 years, ideally guiding them toward their next entrepreneurial venture. I prefer to work with those who view success as a collective endeavor rather than a competitive race.

What successes and challenges have you encountered in your investment journey so far?

When I first started discussing AI, machine learning, and their applications in medicine over a decade ago, skepticism was the prevalent sentiment, with many doubting its feasibility or value. Witnessing the shift in attitudes has been rewarding.

It took me a while to recognize that, no matter how promising new technologies may be, market strategy is of utmost importance. I often advise my founders, particularly those with scientific or product-focused backgrounds, to redirect their creativity and intellect toward market strategies, as navigating the go-to-market terrain can be as challenging, if not more so, than the technology itself.

Could you elaborate on how you are structuring this new firm differently from your role at a16z?

We are following a distinctly different model now… VZ derives from the initials of my name, Vijay, and my co-founder, Zach Werner—he represents the “Z.” We intentionally keep a small team… on the investment side, it’s just the two of us. Although we initially considered hiring associates, our established processes have rendered that unnecessary.

How do you define “concentrated” in your investment strategy?

We’re not aiming for 30 investments annually… we concentrate on about five focused investments. Adding a new company to our portfolio feels akin to welcoming a new child into a family—it entails substantial responsibility on our part.

Given this structure, who are you competing with for deals?

Interestingly, with this approach, we often find ourselves not competing for the most coveted rounds—investors typically value our participation. This is in contrast to the typical scramble for Series A or B investments. Frequently, investors appreciate our involvement due to our hands-on approach and the distinct value Zach and I contribute. I have immense respect for individuals like Antonio Gracias at Valor for his enduring contributions, and I find inspiration in Thrive’s success with a more focused portfolio as well. Naturally, my experiences at a16z continue to inform my perspective, but these additional examples have expanded my understanding.

What elements of AI and biotechnology do you think are currently oversold?

The reality is that AI can uncover insights beyond human capabilities. The issue arises when claims are made that AI will solve all problems. The hesitation does not stem from doubts about AI itself, but rather from concerns regarding the quality of data. Large language models thrive due to their access to extensive datasets for learning. When critical data is lacking, AI cannot simply compensate for that absence.